Company Overview and News
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
Michael Hill International said the exit from its US business is expected to cost US$4.5 million (NZ$6.1 million) for lease terminations and employee severance costs after it was unable to find a buyer for the jewellery stores.
U.S. President Donald Trump warned the European Union on Tuesday it would get hit with a "big tax" for not treating the United States well when it comes to trade.
Michael Hill International plans to exit 24 of the stores in its unsuccessful Emma & Roe chain at a cost of A$5.8 million ($6.2m) to A$7.9m, repositioning the remaining six stores in the 'demi-fine' jewellery segment.
The profit season underway provides further evidence earnings growth is widening to capture more of the market, supported by synchronised global growth and confidence that consumers are coping with high levels of household debt.
The following slide deck was published by Michael Hill International Ltd. ADR in conjunction with their 2018 Q2 earnings call.
Michael Hill International's 66 per cent profit plunge in its first-half earnings is a one-off blow on the back of plans to exit the US, says a research analyst.
Michael Hill International posted a 66 per cent drop in first-half profit, mainly reflecting A$19.8 million ($21.1m) of provisions to reposition its Emma & Roe chain and to recognise costs of exiting the US market.
New Zealand shares dipped as heightened global volatility continued to subside, while insurer CBL Corp was suspended pending regulatory investigations and Fletcher Building signalled another profit warning.
Michael Hill International expects first-half earnings will more than halve with A$20 million ($21.7m) coming from the jewellery chain's exit from the US and scaling back its Emma & Roe branded store footprint.
Michael Hill International didn't have the brand awareness or the budget to penetrate the US market, forcing its withdrawal, the retailer's boss says.
New Zealand shares were mixed as trading picked up, with A2 Milk Co and Mercury Energy gaining while Metro Performance Glass fell.
Michael Hill International, the jewellery chain founded by its namesake, will wind up its US operations after a decade-long investment failed to build a profitable business, and is overhauling its Emma & Roe jewellery line.
New Zealand shares dipped, led lower by Fisher & Paykel Healthcare and Pushpay Holdings, albeit in light volume as market participants return slowly.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET